US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

CytoMed Therapeutics Limited - Ordinary Shares (NQ:GDTC)

0.9200 +0.0201 (+2.23%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CytoMed Therapeutics Limited - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector
Via Get News
News headline image
CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector
Via Get News
News headline image
CytoMed, a Singapore Biotech, Revolutionizes Cancer Treatment Using Donor Immune Cells
Via Get News
News headline image
CytoMed Therapeutics Ltd – A Rising Star in Singapore’s Cancer Biotechnology Sector
Via Get News
Unusual volume stocks in Thursday's session ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Why Did CytoMed Therapeutics Stock Jump 19% Today? ↗
The company said that the proposed acquisition of TC BioPharm will strengthen and deepen its expertise and knowledge in using allogeneic cell therapies for cancer treatment. 
Via Stocktwits
News headline image
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor ↗
CytoMed Therapeutics teams with SunAct for a Phase 1/2 trial on gamma delta T cells in cancer therapy, advancing affordable immunotherapy solutions. 
Via Benzinga
News headline image
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial
From CYTOMED THERAPEUTICS LIMITED
Via GlobeNewswire
< Previous 1 2 3 Next >